{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "licid": "60001118",
    "licUnit": "1",
    "validDate": "2024-12-30 00:00:00.000",
    "issueDate": "2019-12-30 00:00:00.000",
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000111807",
    "prodNameC": "洛希隆注射劑",
    "prodNameE": "Rixathon Concentrate for Solution for Infusion",
    "indicationsName": [
        "1、非何杰金氏淋巴瘤\r\n(1)用於復發或對化學療法有抗性之低惡度B-細胞非何杰金氏淋巴瘤。\r\n(2)併用CVP化學療法用於未經治療之和緩性(組織型態為濾泡型)B細胞非何杰金氏淋巴瘤的病人。\r\n(3)併用CHOP或其他化學療法用於CD20抗原陽性之瀰漫性大型B細胞非何杰金氏淋巴瘤。 \r\n(4)用於做為濾泡性淋巴瘤病人對誘導療法產生反應之後的維持治療用藥。\r\n2、類風濕性關節炎\r\n(1) 與methotrexate併用，適用於治療曾接受一種(含)以上之腫瘤壞死因子(TNF)抑制療法治療但效果不彰，或無法耐受的活動性類風濕性關節炎成人病人。\r\n(2) 與methotrexate併用，經X光檢查已證實可減緩關節結構受損的進展。\r\n3、慢性淋巴球性白血病\r\n(1)適用於與fludarabine及cyclophosphamide併用，做為CD20陽性慢性淋巴球性白血病(CLL)病人的第一線用藥。 \r\n(2)適用於與化學療法併用，做為復發\/頑固性的CD20陽性慢性淋巴球性白血病病人的治療用藥。\r\n3、肉芽腫性血管炎(Granulomatosis with Polyangiitis, GPA)(Wegener’s肉芽腫症)及顯微多發性血管炎(Microscopic Polyangiitis, MPA)：與葡萄糖皮質素(glucocorticoids)併用，適用於治療成人之肉芽腫性血管炎(GPA，亦稱為韋格納肉芽腫症)及顯微多發性血管炎(MPA)。\r\n4.尋常性天疱瘡(Pemphigus Vulgaris, PV)：本品與葡萄糖皮質素(glucocorticoids)併用，適用於治療中度至重度尋常性天疱瘡(PV)的成人病人。"
    ],
    "does": "227D",
    "packageUnit": [
        {
            "packageSpec": "10毫升、50毫升玻璃小瓶裝，100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "0250548E-059F-4603-851C-288C83057AF5",
    "subCategory": [],
    "ingredientsDesc": [
        "Rituximab"
    ],
    "restraintItemsCode": [
        "02",
        "07",
        "1D",
        "91"
    ],
    "applicantName": "台灣山德士藥業股份有限公司",
    "applicantAddr": "臺北市中山區民生東路3段2號8樓",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2024-12-30",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "factoryCode": "1",
            "factoryName": "LEK PHARMACEUTICALS D.D., SLOVENIA",
            "factoryAddr": "VEROVSKOVA 57, SI-1526 LJUBLJANA, SLOVENIA",
            "factoryCompanyAddr": "",
            "countryCode": "SI",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "FSI0004000",
            "factoryInfo": null,
            "qsd": null,
            "factoryMadeIn": null
        },
        {
            "factoryCode": "2",
            "factoryName": "Novartis Pharmaceutical Manufacturing GmbH",
            "factoryAddr": "Biochemiestraße 10, 6336 Langkampfen, Austria",
            "factoryCompanyAddr": "",
            "countryCode": "AT",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FAT0071000",
            "factoryInfo": null,
            "qsd": null,
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013002400",
            "ingredientsName": "Rituximab",
            "ingredientsDesc": "Rituximab",
            "concentDesc": "",
            "concent": "10.0000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [
        {
            "applicantName": "台灣諾華股份有限公司",
            "certNo": "DHA06000111818",
            "approveDocNo": "1130706505",
            "authDate": "2024-03-11",
            "validDate": "2024-12-30"
        }
    ],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FA01"
        }
    ],
    "licBaseId": "0E48E8DD-C84B-4308-922C-4FDCAC7847C2"
}